TheraCryf Secures Korean Patent and Advances Ox-1 Development

Evgen Pharma ( (GB:TCF) ) has issued an announcement.

TheraCryf plc announced the grant of a Korean patent for its Orexin-1R antagonist, enhancing its intellectual property coverage in major markets. The company is progressing with its Ox-1 development program, having identified an optimal formulation for its lead compound and selected a non-rodent species for upcoming toxicity studies. These advancements are crucial for the company’s preparations for clinical trials, potentially strengthening its position in the brain disorder treatment market.

Spark’s Take on GB:TCF Stock

According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.

Evgen Pharma’s overall stock score of 49 reflects ongoing financial and operational challenges, including declining revenues and losses. While the technical analysis shows mixed momentum, recent corporate events provide a positive outlook with strategic initiatives aimed at improving financial stability and advancing key drug development programs.

To see Spark’s full report on GB:TCF stock, click here.

More about Evgen Pharma

TheraCryf plc is a clinical stage drug development company focusing on brain disorders, with a broad clinical and preclinical pipeline addressing conditions such as addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders. The company aims to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programs with mid-size to large pharmaceutical companies for larger trials and commercialization. TheraCryf collaborates with major universities and hospitals and is headquartered in Alderley Park, Cheshire, trading on AIM in London under the ticker symbol TCF.

Average Trading Volume: 2,845,596

Technical Sentiment Signal: Sell

Current Market Cap: £5.16M

See more insights into TCF stock on TipRanks’ Stock Analysis page.